Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Gossamer Bio, Inc.

NASDAQ: GOSS · Life Sciences · 6 alerts · CIK 1728117

Share price
$10.98Close, Nov 16
Market cap
$67.2M
Shares outstanding
6.12MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Gossamer Bio, Inc. filings on SEC EDGAR ↗

4:51 PM ET 8-K
Financial Results

Gossamer Bio Financial Results

Gossamer Bio reported Q3 2026 financial results, highlighting the submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH. The company also noted a structured private placement that provided $25 million upfront and could unlock an additional $125 million upon FDA acceptance of the NDA. Additionally, the company completed a 1-for-80 reverse stock split in September 2026 to regain Nasdaq compliance.

Term
Q3 2026

“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH. Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch. We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”

Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer
4:49 PM ET 10-Q
Financial Results

Gossamer Bio Q3 2026 Results: Net Loss of $48.1M, Loss Narrows

Gossamer Bio reported total revenue of $64.6 million for the nine months ended September 30, 2026, compared to $34.7 million in the prior year, primarily driven by collaboration contracts. Despite the revenue growth, the company recorded a net loss of $77.8 million for the period, impacted by significant non-cash items including a $54.9 million remeasurement of warrant liability and a $43.8 million gain on debt extinguishment.

Key figure
Net loss $48.1M
4:02 PM ET 8-K
Capital Raise

Gossamer Bio Capital Raise

Gossamer Bio stockholders approved the potential issuance of common stock exceeding 20% of outstanding shares in connection with a Securities Purchase Agreement dated August 20, 2026. The approval covers shares issuable upon the exercise of Pre-Funded Warrants, FDA Approval Warrants, and the conversion of Series A-1, A-2, and A-3 Preferred Stock, satisfying Nasdaq Listing Rules 5635(c) and 5635(d).

4:02 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Gossamer Bio Nasdaq/NYSE Compliance Notice

Gossamer Bio has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, resolving a deficiency notice originally received on April 8, 2026. The company achieved compliance following a 1-for-80 reverse stock split that became effective on September 10, 2026, and the matter is now closed.

Counterparty
The Nasdaq Stock Market LLC
4:06 PM ET 8-K
Other 8-K Filing

Gossamer Bio Other 8-K Filing

Gossamer Bio has submitted its first New Drug Application (NDA) to the FDA for seralutinib for the treatment of pulmonary arterial hypertension (PAH). The submission is supported by data from the Phase 3 PROSERA and Phase 2 TORREY studies, following a Pre-NDA meeting with the regulator in June 2026. The FDA is expected to determine whether to accept the application for filing later this year.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.